PHARMA-TECH-HOLDING
8.8.2022 10:52:05 CEST | Business Wire | Press release
Pharma Tech Holding SA (“PTH”) announced today it has secured a CHF 30 million investment to support its portfolio investments from LDA Capital Ltd, a global investment group with expertise in cross border transactions including the agriculture, Agri-tech, and CBD industries.
Established in 2019, PTH is a Swiss based holding company, which invests into innovative businesses with high technological value and scalability potential, mainly in Switzerland and Europe, with a focus on the health-tech, Agri-tech, and functional food.
This investment will allow PTH to mainly invest and support its portfolio company Blue Sky Swisse SA (“BSS”) a JV between PTH and listed company IGEA PHARMA NV (“Igea”), IGPH - ISIN NL0012768675. BSS focuses on the extraction of natural active principles from vegetable matrices, vegetable waste, and renewable sources to deliver B2B products under the form of CBD oil, Terpenes and Waxes. The factory located in Biasca, will be built to the state of art of extraction technology by super critical CO2 and will be energy self-sufficient through the use of solar photovoltaic panels and district heating. BSS will grant for highest CBD quality also due to a proprietary extraction process, starting from the farming performed under strict control and culminating with the immediate freezing of the flowers after harvest, with the target to also sell “all natural” formulations to increase bioavailability thus enhancing the possible applications. Last, but not least, BSS will invest in the agricultural raw material chain and will create an aeroponic green house in Ticino, to deliver a high quality GMP Pharmaceutical CBD oil.
LDA Capital agreed to commit an amount of up to CHF 30 million (the “Capital Commitment”) in cash within a maximum of three years. This Capital Commitment will be released based on drawdowns by PTH, that PTH has the right to exercise at its sole discretion.
“We’re thrilled with this partnership and are so glad that LDA Capital recognizes the value of PTH and its portfolio company, with the aim of creating one of the most innovative hub for health-tech, agri-tech and functional food,” said Sabina Del Nigro, CEO at PTH.
About Pharma Tech Holding: Pharma Tech Holding SA (PTH) is a holding company based in Lugano, Switzerland, which invests into innovative businesses with high technological value and scalability potential, mainly in Switzerland and Europe, with a focus on the health-tech, Agri-tech, and functional food.
About LDA Capital: LDA Capital is a global alternative investment group with expertise in cross border transactions worldwide. Our team has dedicated their careers to international & cross border opportunities having collectively executed over 250 transactions in both the public and private middle markets across 43 countries with aggregate transaction values of over US$11 billion. For more information please visit: www.ldacap.com ; for inquiries please email: info@ldacap.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005153/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Current Chemicals Expands U.S. Production of Rare-Earth Fluorides With New Investment From Momentum Global Ventures5.11.2026 14:14:00 CET | Press release
Current Chemicals receives additional capital to scale U.S. capacity for critical rare-earth fluorides used in magnets, advanced coatings, and alloys Current Chemicals, Inc. (“CCI”), one of the few U.S. companies converting separated rare-earth oxides into the fluorides used to make rare-earth metals and magnets, today announced an additional investment from its lead shareholder, Momentum Global Ventures (“MGV”). The investment will significantly increase CCI’s production of neodymium fluoride, dysprosium fluoride, and other key rare-earth fluorides in Cleveland. The funding adds infrastructure, equipment and engineering staff for fluorides of neodymium, dysprosium, terbium, gadolinium, yttrium, scandium, lanthanum, and lithium for reducing light rare-earths to metal: key inputs for permanent magnets, advanced coatings, and alloys. Neodymium fluoride and dysprosium fluoride are key feedstocks for the metal at the core of high-performance magnets in electric motors, wind turbines and de
iConnections and Preqin, a Part of BlackRock, Announce Collaboration to Bring Institutional Data to Violet, an AI-Powered Capital Introduction Platform5.11.2026 14:00:00 CET | Press release
Preqin's private markets data will be available inside Violet, iConnections' AI-powered capital introduction platform, to help drive networking and greater discovery for attendees of iConnections' Global Alts events iConnections today announced a collaboration with Preqin, a part of BlackRock, that brings one of the industry's leading sources of private markets data and intelligence— spanning fund managers, institutional investors, funds, benchmarks and indices— to Violet, iConnections' AI-powered capital introduction platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105840622/en/ Preqin's data is now inside Violet Powered by Preqin, the integration gives Global Alts attendees access to a broader network of institutional alternatives market participants, inside the same platform where thousands of allocators and managers already discover one another, book meetings and build relationships. “Alternative investing has
SLB OneSubsea Awarded Contract for Lyra Field Development Offshore Norway5.11.2026 13:49:00 CET | Press release
Close collaboration and standardized subsea technology accelerate path to first production Global energy technology company SLB (NYSE: SLB) today announced that its OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104799196/en/ The SLB (NYSE: SLB) OneSubsea™ joint venture has been awarded a contract by Aker BP to deliver subsea production systems, umbilicals and associated services for the Lyra field development, formerly known as Kjøttkake, on the Norwegian Continental Shelf (NCS). Building on nearly a decade of collaboration through Aker BP’s alliance model, Aker BP and SLB OneSubsea worked together from the early stages of the project to shape the development strategy for Lyra. The fie
EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) Sign an Agreement to Pool Their Expertise in Advanced Autonomous Underwater Technologies.5.11.2026 12:48:00 CET | Press release
Signed on 3rd November 2026, the agreement brings together TII’s expertise in autonomous systems and Naval Group’s expertise in naval autonomous systems design, development and integration to explore the development and commercialization of advanced autonomous underwater solutions. The Technology Innovation Institute, the applied-research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has signed an agreement with Naval Group, a global leader in naval defense, to advance cooperation in autonomous underwater technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105684133/en/ EURONAVAL 2026: Naval Group and Technology Innovation Institute (TII) sign an agreement to pool their expertise in advanced autonomous underwater technologies. (Photo: AETOSWire) Announced during Euronaval 2026, the collaboration will focus on exploring opportunities for the joint development and commercialization of uncrewed
BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates5.11.2026 12:00:00 CET | Press release
Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior yearBRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter, an increase of 34% from the prior yearDiluted GAAP Earnings per American Depository Share (ADS) of $3.28 for the third quarter; non-GAAP diluted Earnings per ADS of $4.59 for the third quarterRaised 2026 total revenue guidance to $6.9 to $7.0 billion; GAAP operating income of $1.2 to $1.3 billion, non-GAAP operating income of $1.9 to $2.0 billion BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the third quarter of 2026. John V. Oyler, Co-Founder, Chairman, and CEO, BeOne, said: “Our strong third quarter results and raised full-year guidance reflect continued rapid global growth and leadership in hematology, anchored by our foundational BTK inhibitor BRUKINSA, which drives powerful and sustained responses in pat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom